CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0534 (clinicaltrials.gov NCT No: NCT01712308)
Title:A PHASE-2, PROSPECTIVE, OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND EFFICACY OF SOTATERCEPT (ACE-011) IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN) -ASSOCIATED MYELOFIBROSIS AND ANEMIA
Principal Investigator:Srdan Verstovsek
Treatment Agent:Sotatercept – ACE-011
Study Status:Open
Study Description:The goal of this clinical research study is to learn if sotatercept can help to
control MPN-associated myelofibrosis and anemia. The safety of this drug will
also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Sotatercept – ACE-011
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults